General Proximity pioneers next-generation medicines by controlling biological processes through proximity. Redefining the future of medicine for all humankind. Backed by Y Combinator and Felicis.
About the role
We are seeking an exceptional medicinal chemist to join our Chemistry and Drug Discovery team. This is a rare opportunity to help build a next-generation drug discovery company from the ground up and contribute directly to the creation of a novel class of therapeutics.
What they're looking for
- PhD in Chemistry, Medicinal Chemistry, or a related field
- A minimum of 5 years of industry experience in small-molecule drug discovery
- Strong foundation in medicinal chemistry and its application to disease-focused drug discovery
- Experience designing, synthesizing, and optimizing induced proximity medicines, including PROTACs or related approaches
- Experience across hit finding, hit-to-lead, and lead optimization, including experience building follow-up strategy for HTS, DNA-encoded or phenotypic screening follow-up
- Demonstrated success optimizing compounds for oral exposure and interpreting pharmacokinetic data across multiple species
More about this role
General Proximity is a seed-stage startup developing the next generation of induced proximity medicines (IPMs). Our OmniTAC drug discovery engine furnishes molecules that co-opt existing cellular machinery to overcome therapeutic challenges, which have remained unapproachable to other modalities for decades.
We are seeking a first-rate medicinal chemist to help us pioneer this uncharted frontier of drug discovery.
A long-standing challenge in drug discovery is the development of molecules capable of modulating difficult or "undruggable" targets. Disease-causing proteins can be dysfunctional in many different ways, but our armamentarium for fixing them is quite limited. The most common mechanism of action for FDA-approved drugs is inhibition [1] , but there are many other possible perturbation types whose potential remains unrealized.
General Proximity is a seed-stage drug discovery company developing a novel platform technology to solve this problem. We make bifunctional drugs that induce the modification of drug targets by existing cellular machinery (rather than through direct modulation by the drug, the classical approach).
Historically, the development of technologies that...
Browse similar: Startup jobs · San Francisco Bay Area